Overview

Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy

Status:
Completed

Trial end date:
2020-04-30

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to see how well the combination of Abraxane and gemcitabine works in people with advanced adenocarcinoma NSCLC who have already had treatment for their disease. Gemcitabine and Abraxane are FDA approved chemotherapies; however, the FDA has not approved this combination in the treatment of this specific type of cancer. Patients may continue to receive the study drugs until their disease gets worse or they have unacceptable side effects.

Phase:

Phase 2

Details

Lead Sponsor:

Abramson Cancer Center of the University of Pennsylvania

Treatments:

Albumin-Bound Paclitaxel
Gemcitabine
Paclitaxel